3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
36
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Burkitt Lymphoma
7
Neoplasms
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Leukemia
6
Lymphoma, B-Cell
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Recurrence
3
Neoplasm Metastasis
3
Lymphoma, T-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Pain
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Neoplasms
2
Hematologic Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Sezary Syndrome
1
Interventions
pembrolizumab
11
epacadostat
2
Paclitaxel
2
spartalizumab
1
ribociclib
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Gemcitabine
1
Docetaxel
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Axitinib
1
AZD 6244
1
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Prednisone
×
Clear all
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts